Tharimmune (NASDAQ:THAR) Shares Up 1.6% – Should You Buy?

Tharimmune, Inc. (NASDAQ:THAR) shares were up 1.6% during trading on Wednesday . The company traded as high as $1.91 and last traded at $1.90. Approximately 378,180 shares changed hands during mid-day trading, a decline of 74% from the average daily volume of 1,476,877 shares. The stock had previously closed at $1.87.

Tharimmune Trading Up 1.6%

The firm has a market cap of $71.69 million, a P/E ratio of -0.48 and a beta of 1.43. The business has a 50-day moving average of $2.49 and a two-hundred day moving average of $3.35.

Institutional Trading of Tharimmune

A number of hedge funds have recently made changes to their positions in THAR. XTX Topco Ltd bought a new position in Tharimmune in the 2nd quarter valued at approximately $25,000. Drucker Wealth 3.0 LLC grew its holdings in Tharimmune by 150.0% during the 4th quarter. Drucker Wealth 3.0 LLC now owns 25,337 shares of the company’s stock worth $77,000 after acquiring an additional 15,202 shares during the last quarter. State Street Corp grew its holdings in Tharimmune by 109.0% during the 4th quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after acquiring an additional 19,100 shares during the last quarter. Franklin Resources Inc. acquired a new position in Tharimmune in the 2nd quarter valued at approximately $88,000. Finally, Aristides Capital LLC bought a new position in shares of Tharimmune during the fourth quarter valued at $253,000. 1.16% of the stock is owned by institutional investors and hedge funds.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.